Please assess the completion status of the following clinical trial:

Trial Title: Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
KEY Inclusion Criteria:~1. Male and female patients ≥ 18 years with a body weight ≥ 45 kg.~2. Microscopic confirmation of acute uncomplicated P. falciparum using by Giemsa-stained thick film.~3. P. falciparum parasitaemia of 500 to 50 000 parasites/µL.~4. Axillary temperature ≥ 37.5ºC or oral/tympanic/rectal temperature ≥ 38.0ºC; or history of fever during the previous 24 hours.~5. Written informed consent must be obtained before any study assessment is performed. If the patient is unable to write, then a witnessed consent according to local ethical standards is permitted.~KEY Exclusion Criteria:~1. Mixed Plasmodium infections.~2. Signs and symptoms of severe malaria according to World Health Organization (WHO) 2016 criteria (WHO 2016).~3. Known liver abnormalities, liver cirrhosis (compensated or decompensated), known active or history of hepatitis B or C (testing not required), known gallbladder or bile duct disease, acute or chronic pancreatitis.~4. Clinical or laboratory evidence of any of the following:~5. AST/ALT \> 1.5 x the upper limit of normal range (ULN), regardless of the level of total bilirubin~6. AST/ALT \> 1.0 and ≤ 1.5 x ULN and total bilirubin is \> ULN~7. Total bilirubin \> 2 x ULN, regardless of the level of AST/ALT~8. History of photodermatitis/increased sensitivity to sun.~9. Pregnant or nursing (lactating) women.~10. Known disturbances of electrolyte balance, e.g. hypokalemia, hypocalcemia or hypomagnesemia.~11. Moderate to severe anemia (Hemoglobin level \<8 g/dL).~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm 1: KAE609 10 mg Single Dose (SD) (Type: EXPERIMENTAL): KAE609 10 mg once daily (QD) for 1 day
- Treatment arm 2:KAE609 25 mg SD (Type: EXPERIMENTAL): KAE609 25 mg once daily (QD) for 1 day
- Treatment arm 3:KAE609 10 mg 3 Days (Type: EXPERIMENTAL): KAE609 10 mg (QD) for 3 days
- Treatment arm 4:KAE609 50 mg SD (Type: EXPERIMENTAL): KAE609 50 mg once daily (QD) for 1 day
- Treatment arm 5:KAE609 25 mg 3 Days (Type: EXPERIMENTAL): KAE609 25 mg once daily (QD) for 3 days
- Treatment arm 6:KAE609 75 mg SD (Type: EXPERIMENTAL): KAE609 75 mg once daily (QD) for 1 day
- Treatment arm 7:KAE609 50 mg 3 Days (Type: EXPERIMENTAL): KAE609 50 mg once daily (QD) for 3 days
- Treatment arm 8: KAE609 150 mg SD (Type: EXPERIMENTAL): KAE609 150 mg once daily (QD) for 1 day
- Treatment arm 9: Coartem Control (Type: ACTIVE_COMPARATOR): Coartem® control

Based on this trial design, predict the completion outcome and termination type (if applicable).